Impact of Preprocedural Anemia on Outcomes ofPatients With Mitral Regurgitation Who UnderwentMitraClip Implantation

Kaneko, Hidehiro; Neuß, Michael; Okamoto, Maki; Weissenborn, Jens; Butter, Christian

doi:10.1016/j.amjcard.2018.05.028

Cited by 13 publications

(12 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…had demonstrated a lower survival in anemic patients at 6 months. Similar to the current study, both prior studies have shown a higher burden of comorbidities among anemic patients, including chronic kidney disease, diabetes mellitus, and hypertension [11][12]. The current analysis showed that patients with anemia had a higher prevalence of coagulopathy, thrombocytopenia, and peripheral vascular diseases.…”

Section: Figure 3: Summary Figuresupporting

confidence: 86%

“…However, the mid-term and long-term outcomes post-TAVR were found to be worse in anemic patients [ 15 - 17 ]. Prior single-center studies regarding anemia in patients undergoing TMVr reported a prevalence of up to 56% [ 11 - 12 ]. This difference in prevalence can be related to the ICD-9 codes-based identification of anemia in the current analysis and potentially overestimating coexisting anemia in smaller single-center studies previously [ 11 - 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…The study by Hellhammer et al [11]. showed no difference in 30-day mortality and in-hospital complications among anemic and non-anemic patients undergoing TMVr, whereas Kaneko et al [12]. had demonstrated a lower survival in anemic patients at 6 months.…”

Section: Figure 3: Summary Figurementioning

confidence: 96%

“…Anemia is a commonly encountered comorbidity in elderly patients with cardiovascular disorders [8][9]. Its association with poor outcomes in several cardiovascular disorders, cardiac surgeries, and percutaneous procedures is well-described [9][10][11][12][13][14][15][16][17]. Among the percutaneous valvular interventions, prior studies regarding anemia in patients undergoing transcatheter aortic valve replacement (TAVR) have shown higher mortality and increased requirement for blood transfusions [15][16][17].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Anemia Among Patients Undergoing Transcatheter Mitral Valve Repair: From the National Inpatient Sample in the United States

Bhardwaj¹,

Karuparthi²,

Desai³

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

Section: Figure 3: Summary Figuresupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Figure 3: Summary Figurementioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Anemia Among Patients Undergoing Transcatheter Mitral Valve Repair: From the National Inpatient Sample in the United States

Bhardwaj¹,

Karuparthi²,

Desai³

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Finally, one study reported the negative prognostic impact of pre-procedural anemia in patients who underwent PMVR with a higher baseline NT-proBNP level [56].…”

Section: Nps and Other Biomarkersmentioning

confidence: 99%

Functional Role of Natriuretic Peptides in Risk Assessment and Prognosis of Patients with Mitral Regurgitation

Gallo

Forte

Stanzione

et al. 2020

JCM

View full text Add to dashboard Cite

The management of mitral valve regurgitation (MR), a common valve disease, represents a challenge in clinical practice, since the indication for either surgical or percutaneous valve replacement or repair are guided by symptoms and by echocardiographic parameters which are not always feasible. In this complex scenario, the use of natriuretic peptide (NP) levels would serve as an additive diagnostic and prognostic tool. These biomarkers contribute to monitoring the progression of the valve disease, even before the development of hemodynamic consequences in a preclinical stage of myocardial damage. They may contribute to more accurate risk stratification by identifying patients who are more likely to experience death from cardiovascular causes, heart failure, and cardiac hospitalizations, thus requiring surgical management rather than a conservative approach. This article provides a comprehensive overview of the available evidence on the role of NPs in the management, risk evaluation, and prognostic assessment of patients with MR both before and after surgical or percutaneous valve repair. Despite largely positive evidence, a series of controversial findings exist on this relevant topic. Recent clinical trials failed to assess the role of NPs following the interventional procedure. Future larger studies are required to enable the introduction of NP levels into the guidelines for the management of MR.

show abstract

Impact of chronic kidney disease on in‐hospital outcomes and readmission rate after edge‐to‐edge transcatheter mitral valve repair

Sawalha

Al‐Akchar

Ibrahim

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Background Transcatheter mitral valve repair (TMVR) is a treatment option for patients with 3+ or greater mitral regurgitation who cannot undergo mitral valve surgery. Outcomes in patients with chronic kidney disease (CKD) and end stage renal disease (ESRD) are unclear. We sought to evaluate the TMVR in‐hospital outcomes, readmission rates and its impact on kidney function. Methods Data from 2016 National Readmission Database was used to obtain all patients who underwent TMVR. Patients were classified by their CKD status: no CKD, CKD, or ESRD. The primary outcomes were: in‐hospital mortality, 30‐ and 90‐day readmission rate, and change in CKD status on readmission. Multivariable logistic regression analysis was used to assess in‐hospital, readmission outcomes and kidney function stage. Results A total of 4,645 patients were assessed (mean age 78.5 ± 10.3 years). In‐hospital mortality was higher in patients with CKD (4.0%, odds ratio [OR]:2.01 [95% CI, confidence interval: 1.27–3.18]) and ESRD (6.6%, OR: 6.38 [95% CI: 1.49–27.36]) compared with non‐CKD (2.4%). 30‐day readmission rate was higher in ESRD versus non‐CKD patients (17.8% vs. 10.4%, OR: 2.24 [95% CI: 1.30–3.87]) as was 90‐day readmission (41.2% vs. 21% OR: 2.51 [95% CI:1.70–3.72]). Kidney function improved in 25% of patients with CKD stage 3 and in 50% with CKD stage 4–5 at 30‐and 90‐day readmission. Incidence of AKI, major bleeding, and respiratory failure were higher in CKD group. Conclusions Patients with CKD and ESRD have worse outcomes and higher readmission rate after TMVR. In patients who were readmitted after TMVR, renal function improved in some patients, suggesting that TMVR could potentially improve CKD stage.

show abstract

Impact of Preprocedural Anemia on Outcomes ofPatients With Mitral Regurgitation Who UnderwentMitraClip Implantation

Cited by 13 publications

References 44 publications

Anemia Among Patients Undergoing Transcatheter Mitral Valve Repair: From the National Inpatient Sample in the United States

Anemia Among Patients Undergoing Transcatheter Mitral Valve Repair: From the National Inpatient Sample in the United States

Functional Role of Natriuretic Peptides in Risk Assessment and Prognosis of Patients with Mitral Regurgitation

Impact of chronic kidney disease on in‐hospital outcomes and readmission rate after edge‐to‐edge transcatheter mitral valve repair

Contact Info

Product

Resources

About